CS
NBIX icon

Credit Suisse’s Neurocrine Biosciences NBIX Stock Holding History

Credit Suisse’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-15,600
Closed -$1.41M – 4274
2019
Q3 		$1.41M Buy
+15,600
New +$1.46M ﹤0.01% 2747

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Credit Suisse's NBIX Position: Q1 2024 in Review

Credit Suisse reduced its Neurocrine Biosciences (NBIX) stake by 15% in Q1 2024, selling an estimated $4.24M and leaving 169,161 shares worth $23.3M. The position accounts for 0.02% of the portfolio, ranked #590.

Credit Suisse first reported a position in NBIX in Q2 2013 and has held it in 44 quarters since. The position peaked at $38.8M in Q3 2018. 590 funds tracked by Wall St. Rank hold NBIX as of Q1 2024.

  • Credit Suisse held 169,161 shares of Neurocrine Biosciences worth $23.3M as of Q1 2024.
  • Credit Suisse sold 31,020 Neurocrine Biosciences shares in Q1 2024, an estimated $4.24M.
  • Neurocrine Biosciences made up 0.02% of Credit Suisse's portfolio in Q1 2024, its #590 holding.
  • Credit Suisse first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 44 quarters since.
  • Credit Suisse's Neurocrine Biosciences position peaked at $38.8M in Q3 2018.
  • 590 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.